Design Therapeutics (NASDAQ:DSGN) Given New $4.00 Price Targ

Design Therapeutics (NASDAQ:DSGN – Free Report) had its price target decreased by Royal Bank of Canada from $7.00 to $4.00 in a report published on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the stock. A number of other research firms have also issued reports on DSGN. SVB […]

Related Keywords

Blackrock , Nova Scotia , Canada , Rodneyw Lappe , Deepa Prasad , Piper Sandler , Leerink Partnrs , Royal Bank , Avoro Capital Advisors , Securities Exchange Commission , Design Therapeutics Inc , Design Therapeutics Company Profile , Blackrock Inc , Vanguard Group Inc , Design Therapeutics , Free Report , Director Deepa Prasad , Exchange Commission , Director Rodney , Capital Advisors , Street Corp , Vanguard Group , Get Free Report , Friedreich Ataxia , Myotonic Dystrophy , Design Therapeutics Daily , Nasdaq Dsgn , Dsgn , Medical , Lower Price Target , Royal Bank Of Canada ,